Format

Send to

Choose Destination
Oncogene. 2014 Jul 24;33(30):3894-907. doi: 10.1038/onc.2013.352. Epub 2013 Sep 16.

Predictive biomarkers for cancer therapy with PARP inhibitors.

Author information

1
1] INSERM, U848, Villejuif, France [2] Institut Gustave Roussy, Villejuif, France [3] Université de Paris Sud, Villejuif, France.
2
1] Regina Elena National Cancer Institute, Roma, Italy [2] National Institute of Health, Rome, Italy.
3
1] Institut Gustave Roussy, Villejuif, France [2] Université de Paris Sud, Villejuif, France [3] CNRS UMR8200, Villejuif, France.
4
1] INSERM, U848, Villejuif, France [2] Institut Gustave Roussy, Villejuif, France [3] Université de Paris Sud, Villejuif, France [4] Metabolomics Platform, Institut Gustave Roussy, Villejuif, France [5] Centre de Recherche des Cordeliers, Paris, France [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France [7] Faculty of Medicine, Université Paris Descartes, Paris, France.

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms, in particular the homologous recombination pathway, for instance due to BRCA mutations. Thus, deficient DNA repair provides a framework for the success of PARP inhibitors in medical oncology. Here, we review encouraging results obtained in recent clinical trials investigating the safety and efficacy of PARP inhibitors as anticancer agents. We discuss emerging mechanisms of regulation of homologous recombination and how inhibition of DNA repair might be used in cancer therapy. We surmise that the identification of patients that are likely to benefit from PARP inhibition will improve the clinical use of PARP inhibitors in a defined target population. Thus, we will place special emphasis on biomarker discovery.

PMID:
24037533
DOI:
10.1038/onc.2013.352
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center